Repligen (NASDAQ:RGEN) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Repligen (NASDAQ:RGEN - Free Report) from a buy rating to a hold rating in a research note issued to investors on Sunday.

A number of other analysts have also recently weighed in on the company. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target on the stock. Royal Bank Of Canada dropped their target price on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $172.83.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $0.37 during trading on Friday, reaching $126.81. The stock had a trading volume of 306,437 shares, compared to its average volume of 727,666. The firm's 50 day moving average price is $127.70 and its two-hundred day moving average price is $140.50. Repligen has a one year low of $102.97 and a one year high of $182.52. The stock has a market cap of $7.12 billion, a PE ratio of -282.23, a P/E/G ratio of 3.56 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same period in the prior year, the company earned $0.28 earnings per share. The firm's revenue was up 10.4% compared to the same quarter last year. On average, research analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RGEN. Signaturefd LLC raised its holdings in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new position in shares of Repligen during the 4th quarter valued at $29,000. Raiffeisen Bank International AG bought a new stake in shares of Repligen in the 4th quarter worth $29,000. Twin Tree Management LP acquired a new stake in shares of Repligen in the first quarter valued at $29,000. Finally, Itau Unibanco Holding S.A. bought a new position in Repligen during the fourth quarter valued at about $40,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.